Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

N. Gara, X. Zhao, M. T. Collins, W. H. Chong, D. E. Kleiner, T. Jake Liang, M. G. Ghany, J. H. Hoofnagle

Research output: Contribution to journalArticle

Abstract

Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (

Original languageEnglish (US)
Pages (from-to)1317-1325
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume35
Issue number11
DOIs
StatePublished - Jun 2012
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B'. Together they form a unique fingerprint.

  • Cite this

    Gara, N., Zhao, X., Collins, M. T., Chong, W. H., Kleiner, D. E., Jake Liang, T., Ghany, M. G., & Hoofnagle, J. H. (2012). Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 35(11), 1317-1325. https://doi.org/10.1111/j.1365-2036.2012.05093.x